RESUMO
Increasing information concerning molecular biology of viruses and virus-cell interactions makes it possible to use viruses as a tool in effort to treat cancer diseases. As a rule, tumor cells are highly sensitive to viruses that may be used in cancer therapy. Therewith, applications of viral oncolysis in treatment of cancer diseases assume maximum possible safety of used viruses for patient and environment. Human enteroviruses are one of the most convenient sources to generate oncolytic viruses. Many of enteroviruses are non-pathogenic for humans or cause mild disease. Progress in genetic engineering permits to develop attenuated enterovirus variants with high safety and selectivity. This review focuses on the main members of Enterovirus genus, such as Coxsackieviruses, and vaccine strains as promising source for development of oncolytic agents, applicable for cancer therapy. It reviews data concerning recently developed and tested oncolytic variants of enteroviruses and discusses perspectives of their application in cancer therapy and problems, concerning their improvement and practical use.
Assuntos
Vacinas Anticâncer/genética , Enterovirus/imunologia , Genoma Viral , Neoplasias/tratamento farmacológico , Neoplasias/prevenção & controle , Vírus Oncolíticos/imunologia , Vacinas Virais/genética , Antineoplásicos/administração & dosagem , Antineoplásicos/imunologia , Vacinas Anticâncer/imunologia , Enterovirus/genética , Engenharia Genética , Humanos , Neoplasias/imunologia , Terapia Viral Oncolítica/métodos , Vírus Oncolíticos/genética , Vacinas Virais/imunologia , Replicação ViralRESUMO
A recombinant pSC13D6 plasmid DNA was constructed based on cDNA fragments of genes encoding variable domains of heavy and light chains of the MKA 13D6 monoclonal antibody against glycoprotein of the tick-borne encephalitis (TBE) virus. This plasmid provided expression in Escherichia coli cells of the sc13D6 single-chain antibody against the TBE virus. The produced antibodies could bind to the TBE virus, strain 205, and the TBE virus recombinant E protein. The affinity constant of purified sc13D6 was (3.0 +/- 0.2) x 10(7) M(-1) for the equilibrium state and (2.8 +/- 0.3) x 10(7) M(-1) in the case of antigen-antibody formation on the surface. The obtained single-chain antibody could inhibit the infection potency of the TBE virus on a monolayer of eukaryotic cells. The calculated IC50 value for sc13D6 was 16.7 microg/ml.
